Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) have earned an average rating of “Buy” from the twelve ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating on the […]
Equities analysts expect that Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) will announce earnings per share of ($0.77) for the current quarter, Zacks reports. Ten analysts have issued estimates for Fate Therapeutics’ earnings. The highest EPS estimate is ($0.63) and the lowest is ($0.86). Fate Therapeutics reported earnings of ($0.48) per share in the same […]
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) have earned an average rating of “Buy” from the twelve research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) General Counsel Cindy Tahl sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, April 1st. The stock was sold at an average price of $38.85, for a total value of $971,250.00. The transaction was disclosed in a filing with the SEC, which is […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) and GreenLight Biosciences (NASDAQ:GRNA – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends. Earnings & Valuation This table compares Fate Therapeutics and GreenLight […]